HERZELIYA, Israel, March 15, 2012 /PRNewswire/ -- - The agreement is expected to assist the Company with safety and efficacy data that may focus

HERZLIYA, Israel, March 25, 2011 /PRNewswire-FirstCall/ -- - MinoGuard, a Private Biotechnology Company Developing Drugs for Mental Health Diseases, With its Lead Compound, SAM-101 for the Treatment of Schizophrenia; - MinoGuard Successfully Completed a 70 Patient Phase 2a Clinical Trial in Schizophrenia - use of the Drug Indicated Improvement of the Positive Symptoms of the Disease as well as Decrease of its Negative Symptoms XTL announced on March 24, 2011, it entered into a term sheet to acquire the activity of MinoGuard Ltd.

Bio-Gal is Developing a Drug for the Treatment of Multiple Myeloma ("MM") Patients - Research and Clinical Observations of MM Terminal Patients by Bio-Gal Suggests That Treatment with Erythropoietin Suppresses the Disease, Prolonging and Improving the Patients' Lives. - XTL is Commencing Preparations to Begin a Phase 2 Clinical Trial in Multiple Myeloma Patients - Under the Transaction, XTL Received $1.5 Million in Cash XTL has announced that their purchase of Bio-Gal was completed successfully.